EMBRYOLY Integrates with Prominent Electronic Medical Record System VRepro to improve Workflow Efficiency in IVF Centers 30.09.2024 ImVitro has announced the integration of its Artificial Intelligence (AI)-powered embryo management software, EMBRYOLY, with the prominent electronic medical record (EMR) VRepro available in fertility clinics across Europe, Central and South America, and…
Read MoreAbout us & our product ImVitro’s SaaS platform EMBRYOLY is an AI-powered software. EMBRYOLY’s core feature provides a ranking based on the embryo’s morphokinetics as well as a subsequent transfer priority recommendation personalized to the patient for increased accuracy. See our product page for more information! The challenge In many cases,…
Read MoreAbout us & our product ImVitro’s SaaS platform EMBRYOLY is an AI-powered software. EMBRYOLY’s core feature provides a ranking based on the embryo’s morphokinetics as well as a subsequent transfer priority recommendation personalized to the patient for increased accuracy. See our product page for more information! The challenge Ranking embryos is…
Read MoreAnswer these questions to download a personalized and concise report about how EMBRYOLY will positively impact your clinic’s productivity. 1. All questions are compulsory. If unsure, we suggest some values as per our customer’s feedback and the literature that you could use as rough estimates. If the embryologist is in…
Read MoreAbout us & our product ImVitro’s SaaS platform EMBRYOLY is an AI-powered software. EMBRYOLY’s core feature provides a ranking based on the embryo’s morphokinetics as well as a subsequent transfer priority recommendation personalized to the patient for increased accuracy. See our product page for more information! The challenge While evaluating the…
Read MoreAbout us & our product ImVitro’s SaaS platform EMBRYOLY is an AI-powered software. EMBRYOLY’s core feature provides a ranking based on the embryo’s morphokinetics as well as a subsequent transfer priority recommendation personalized to the patient for increased accuracy. See our product page for more information! The challenge Embryo morphokinetics is…
Read MoreAbout us & our product ImVitro’s SaaS platform EMBRYOLY is an AI-powered software. EMBRYOLY’s core feature provides a ranking based on the embryo’s morphokinetics as well as a subsequent transfer priority recommendation personalized to the patient for increased accuracy. See our product page for more information! The challenge Embryo evaluation is…
Read MoreAbout us & our product ImVitro’s SaaS platform EMBRYOLY is an AI-powered software. EMBRYOLY’s core feature provides a ranking based on the embryo’s morphokinetics as well as a subsequent transfer priority recommendation personalized to the patient for increased accuracy. See our product page for more information! The challenge Many aneuploid embryos…
Read MoreAbout us & our product ImVitro’s SaaS platform EMBRYOLY is an AI-powered software. EMBRYOLY’s core feature provides a ranking based on the embryo’s morphokinetics as well as a subsequent transfer priority recommendation personalized to the patient for increased accuracy. See our product page for more information! The challenge Patients often go…
Read MoreEarlier in the year, we had connected our platform to the Embryoscope® and Embryoscope+® (Vitrolife). We are now thrilled to announce that we are also connected to the GERI® (Genea BiomedX), another major player amongst time-lapse microscopes! One more to go…. Stay tuned!
Read MoreOur CEO and founder Alexandra Boussommier was the guest of the AWS Summit Paris alongside Dali Kilani, CTO of Lifen to talk about conformity and regulatory requirements with AWS cloud computing. Both founders explore how their companies are using cloud computing technology in healthcare and advises other aspiring founders. For…
Read MoreOur CEO and founder Alexandra Boussommier was accepted into the adastra.ventures founder bootcamp “Get to Even”! We are excited for Alexandra’s participation and grateful for Ad Astra‘s support of female founders and leaders.
Read MoreIt is a great honor to announce that ImVitro is part of the the digital health incubator led by Bpifrance and Fondation Université Paris, alongside the startups Ma Clinique Digitale, MedInBox, Mobaspace, MyPL and Tricky. Thanks to both for their support and trust!
Read MoreWomen’s health and infertility is at the heart of attention in Europe and investors are aware of it. It is wonderful to see ImVitro being mentioned by Cherry Ventures as one of the key actors in Europe that works to improve IVF outcomes and reduce the time to pregnancy. More…
Read MoreCela fait plus de 2 ans que nous avons entamé notre projet, et les centres d’INOVIE fertilité ont été parmi les premiers à y croire. Ils sont donc aujourd’hui parmi les premiers à nous faire des retours sur notre interface qui commence à être mise à disposition de nos partenaires…
Read MoreToday, our CEO Alexandra Boussommier is invited to talk with a great panel of researchers and entrepreneurs in front of students & young researchers at Accorhotels Arena for the yearly event organized by BPIFRANCE “La Deeptech fait son BIG !”. The session mediated by Antoine petit (PDG CNRS) is called…
Read MoreAlthough ImVitro helps patient of all genders, and is therefore not just about FemTech, it is great to see ImVitro being mentioned in Sifted as one of the Europeans start-ups in fem-tech to watch out for! More info here: https://sifted.eu/articles/femtech-startups-to-watch-according-to-vcs/
Read MoreTo learn more about IVF and how artificial intelligence could help to address some of the challenges associated with the technique, check out the interview of our CEO Alexandra Boussommier about ImVitro published on TechnologyNetworks. It is great to see our work talked on such a well known media.
Read MoreMolly Heath originally contacted ImVitro in the context of EF’s Focus on FemTech series. Our discussion was a great opportunity to reflect on the fact that IVF is actually not just a woman’s issue: enjoy the read!
Read MoreLast week, ImVitro was invited on “Check up Santé” on BFM Business as one of 3 health startups (along with Posos and Healthy Mind) that spinned off Station F to showcase how important incubators such as Station F can be in a startup journey, along with its many accelerator programs…
Read MoreWomen in Science aim is to promote the role of women in data science, who are underrepresented in this field as well as other science related fields, both in research, industry and start-ups. Alexandra was invited to discuss ImVitro and her career path during the event WISE II (Women in…
Read MoreChetan Halaui interviews Alex on his breakfast show to learn more about her journey as a founder and what ImVitro is currently working on. Thank you Chet for this opportunity! Click here to see the interview
Read MoreIn November 2019, ImVitro was selected as one of the future 40 promising start ups at Station F. In this interview, Station F followed up 6 months later with the company, giving Alexandra the chance to re-explain the vision and mission of the company. Thanks again to Station F for…
Read MoreAlexandra gives a talk for the Paris Biotech group about the use of AI applied to IVF and more generally about her transition from academia to founding a company. Thanks again to Yulia Dembitskaya for organizing this!
Read MoreImVitro receives the French Tech Emergence grant 90K Euros grant from the BPI aimed at supporting innovative companies focused on R&D Thanks to BPI for their support!
Read MoreFor our francophone readers, check out the article about ImVitro today published on the newspaper Cnews here.
Read MoreToday, ImVitro was selected as one of the future 40 promising start ups at Station F. To learn more about us, check out the pitch of our CEO Alexandra Boussommier here. Thanks to Station F for this opportunity!
Read MoreTake a look at the very beginning of ImVitro’s journey (and that of other EF startups) as told by the accelerator Entrepreneur First!
Read More